Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology.
adrenal cortex
eplerenone
mineralocorticoid receptor antagonists
spironolactone
steroids
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
20 Apr 2021
20 Apr 2021
Historique:
received:
26
03
2021
revised:
14
04
2021
accepted:
17
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
Mineralocorticoid receptor antagonists (MRAs) are a class of anti-hypertensive drugs that act by blocking aldosterone action. The aim of this study was to evaluate whether the MRAs spironolactone and eplerenone influence adrenal cortical physiology and morphology. Spontaneous hypertensive rats (SHR,
Identifiants
pubmed: 33924172
pii: biomedicines9040441
doi: 10.3390/biomedicines9040441
pmc: PMC8074383
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Fundação para a Ciência e a Tecnologia
ID : UIDB/00215/2020
Organisme : Fundação para a Ciência e a Tecnologia
ID : UIDP/00215/2020
Références
Horm Metab Res. 2009 Jan;41(1):35-9
pubmed: 18819053
J Transl Med. 2011 Oct 21;9:180
pubmed: 22017794
Biochem Pharmacol. 1985 Jan 15;34(2):189-94
pubmed: 2981534
Vasc Health Risk Manag. 2017 Oct 16;13:403-411
pubmed: 29081661
Mol Cell Endocrinol. 2009 Apr 29;302(2):230-6
pubmed: 18812209
Cardiology. 2017;138(1):55-62
pubmed: 28571007
Am J Clin Pathol. 1981 Jan;75(1):92-5
pubmed: 7006380
Beitr Pathol. 1973 Nov;150(2):174-87
pubmed: 4129194
Am J Cardiol. 1987 Oct 1;60(10):820-5
pubmed: 3661395
Am J Pathol. 1981 Jun;103(3):404-10
pubmed: 7195152
Arch Pathol. 1975 Aug;99(8):416-20
pubmed: 167703
Physiol Behav. 1992 Jul;52(1):49-57
pubmed: 1529013
Nat Protoc. 2013 Jun;8(6):1149-54
pubmed: 23702831
Endocrinology. 1989 Sep;125(3):1161-7
pubmed: 2547578
Eur Heart J. 2005 Oct;26(20):2193-9
pubmed: 16141258
Am J Cardiol. 1993 Jan 21;71(3):12A-16A
pubmed: 8421998
Mol Cell Endocrinol. 2004 Mar 31;217(1-2):27-31
pubmed: 15134797
Am J Physiol Renal Physiol. 2007 Jul;293(1):F139-47
pubmed: 17376762
Atten Defic Hyperact Disord. 2011 Mar;3(1):1-12
pubmed: 21432613
Endocrinology. 1981 Apr;108(4):1216-21
pubmed: 6258898
Diagn Pathol. 2014 Aug 09;9:147
pubmed: 25108298
Am J Hypertens. 2002 Aug;15(8):709-16
pubmed: 12160194
Clin J Am Soc Nephrol. 2006 Sep;1(5):1039-45
pubmed: 17699324
J Endocrinol. 2005 Jul;186(1):1-20
pubmed: 16002531
Endocr Connect. 2013 Aug 28;2(3):137-45
pubmed: 23925558
Curr Opin Pharmacol. 2015 Apr;21:82-8
pubmed: 25616035
Cardiovasc Res. 1982 Oct;16(10):573-9
pubmed: 7151101
Mol Cell Endocrinol. 2013 May 22;371(1-2):15-9
pubmed: 23089211
Hypertension. 1988 Feb;11(2 Pt 2):I25-32
pubmed: 3346062
J Clin Pathol. 1973 Dec;26(12):949-57
pubmed: 4131694
Sci Rep. 2019 Nov 6;9(1):16098
pubmed: 31695104
J Endocrinol. 2017 Jul;234(1):T125-T140
pubmed: 28634268
J Biochem. 1999 Dec;126(6):1175-83
pubmed: 10578071
Am J Cardiovasc Drugs. 2005;5(1):51-69
pubmed: 15631538
Histochem J. 1979 Jul;11(4):447-55
pubmed: 91593
Mol Cell Endocrinol. 2007 Jul 15;273(1-2):1-5
pubmed: 17587492
Front Neurosci. 2016 Jun 15;10:238
pubmed: 27378832